Trial Outcomes & Findings for Study of UB-312 in Healthy Participants and Parkinson's Disease Patients (NCT NCT04075318)

NCT ID: NCT04075318

Last Updated: 2025-03-06

Results Overview

Number of AEs will be assessed

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

70 participants

Primary outcome timeframe

44 weeks

Results posted on

2025-03-06

Participant Flow

Participant milestones

Participant milestones
Measure	Part A: UB-312 40 mcg UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo
Overall Study STARTED	6	6	6	6	6	6	6	8	7	7	6
Overall Study COMPLETED	6	6	5	6	0	0	0	5	6	7	6
Overall Study NOT COMPLETED	0	0	1	0	6	6	6	3	1	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part A: UB-312 40 mcg n=6 Participants UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg n=6 Participants UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg n=6 Participants UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg n=6 Participants UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg n=6 Participants UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg n=6 Participants UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg n=6 Participants UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo n=8 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg n=7 Participants UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg n=7 Participants UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo n=6 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Total n=70 Participants Total of all reporting groups
Age, Continuous	72.5 years n=5 Participants	65.0 years n=7 Participants	68.5 years n=5 Participants	60.0 years n=4 Participants	65.0 years n=21 Participants	68.3 years n=8 Participants	72.0 years n=8 Participants	64.6 years n=24 Participants	67.4 years n=42 Participants	63.4 years n=42 Participants	61.0 years n=42 Participants	66.1 years n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	2 Participants n=21 Participants	1 Participants n=8 Participants	4 Participants n=8 Participants	4 Participants n=24 Participants	1 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	29 Participants n=42 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	4 Participants n=21 Participants	5 Participants n=8 Participants	2 Participants n=8 Participants	4 Participants n=24 Participants	6 Participants n=42 Participants	5 Participants n=42 Participants	5 Participants n=42 Participants	41 Participants n=42 Participants
Race (NIH/OMB) Other · American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Other · Asian	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Race (NIH/OMB) Other · Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Other · Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants
Race (NIH/OMB) Other · White	6 Participants n=5 Participants	5 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	5 Participants n=21 Participants	6 Participants n=8 Participants	5 Participants n=8 Participants	7 Participants n=24 Participants	7 Participants n=42 Participants	7 Participants n=42 Participants	6 Participants n=42 Participants	66 Participants n=42 Participants
Race (NIH/OMB) Other · More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Other · Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants
Region of Enrollment Netherlands	6 participants n=5 Participants	6 participants n=7 Participants	6 participants n=5 Participants	6 participants n=4 Participants	6 participants n=21 Participants	6 participants n=8 Participants	6 participants n=8 Participants	8 participants n=24 Participants	7 participants n=42 Participants	7 participants n=42 Participants	6 participants n=42 Participants	70 participants n=42 Participants

PRIMARY outcome

Timeframe: 44 weeks

Number of AEs will be assessed

Outcome measures

Outcome measures
Measure	Part A: UB-312 40 mcg n=6 Participants UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg n=6 Participants UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg n=6 Participants UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg n=6 Participants UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg n=6 Participants UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg n=6 Participants UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg n=6 Participants UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo n=8 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg n=7 Participants UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg n=7 Participants UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo n=6 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo
Frequency of Adverse Events	22 TEAEs	31 TEAEs	25 TEAEs	31 TEAEs	24 TEAEs	17 TEAEs	18 TEAEs	25 TEAEs	59 TEAEs	42 TEAEs	20 TEAEs

PRIMARY outcome

Timeframe: 44 weeks

Population: Per protocol population

Number of Participants with Anti-aSyn Antibodies in Blood from Weeks 1 through 45.

Outcome measures

Outcome measures
Measure	Part A: UB-312 40 mcg n=6 Participants UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg n=6 Participants UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg n=5 Participants UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg n=6 Participants UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo n=5 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg n=6 Participants UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg n=7 Participants UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo n=6 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo
Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood	5 Participants	5 Participants	5 Participants	6 Participants	0 Participants	0 Participants	0 Participants	0 Participants	5 Participants	7 Participants	0 Participants

PRIMARY outcome

Timeframe: 44 weeks

Population: per protocol population

Number of Participants with Anti-aSyn Antibodies in CSF from Weeks 1 through 45.

Outcome measures

Outcome measures
Measure	Part A: UB-312 40 mcg n=6 Participants UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg n=6 Participants UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg n=5 Participants UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg n=6 Participants UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo n=5 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg n=6 Participants UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg n=7 Participants UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo n=6 Participants Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo
Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in CSF	1 Participants	4 Participants	3 Participants	6 Participants	0 Participants	0 Participants	0 Participants	0 Participants	4 Participants	1 Participants	0 Participants

Adverse Events

Part A: UB-312 40 mcg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Part A: UB-312 100 mcg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part A: UB-312 40/300 mcg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Part A: UB-312 300 mcg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part A: UB-312 40/1000 mcg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part A: UB-312 1000 mcg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part A: UB-312 2000 mcg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Part A: Placebo

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Part B: UB-312 300/100 mcg

Serious events: 3 serious events

Other events: 7 other events

Deaths: 0 deaths

Part B: UB-312 300 mcg

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Part B: Placebo

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part A: UB-312 40 mcg n=6 participants at risk UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg n=6 participants at risk UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg n=6 participants at risk UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg n=6 participants at risk UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg n=6 participants at risk UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg n=6 participants at risk UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg n=6 participants at risk UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo n=8 participants at risk Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg n=7 participants at risk UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg n=7 participants at risk UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo n=6 participants at risk Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo
Respiratory, thoracic and mediastinal disorders Hospital Acquired Pneumonia (HAP)	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Vascular disorders Unprovoked Deep Venous Thrombosis	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Renal and urinary disorders Urosepsis	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.

Other adverse events

Other adverse events
Measure	Part A: UB-312 40 mcg n=6 participants at risk UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 100 mcg n=6 participants at risk UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/300 mcg n=6 participants at risk UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 300 mcg n=6 participants at risk UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 40/1000 mcg n=6 participants at risk UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part A: UB-312 1000 mcg n=6 participants at risk UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: UB-312 2000 mcg n=6 participants at risk UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13 UB-312: A synthetic peptide-based vaccine	Part A: Placebo n=8 participants at risk Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo	Part B: UB-312 300/100 mcg n=7 participants at risk UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: UB-312 300 mcg n=7 participants at risk UB-312 300 mcg at Weeks 1, 5 and 13 by intramuscular injection UB-312: A synthetic peptide-based vaccine	Part B: Placebo n=6 participants at risk Placebo by intramuscular injection at Weeks 1, 5 and 13 Placebo: Matching placebo
Eye disorders Eye Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Gastrointestinal disorders Gastrointestinal Disorders	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	28.6% 2/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
General disorders General Disorders and Administration Site Conditions	83.3% 5/6 • Number of events 9 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 9 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	100.0% 6/6 • Number of events 13 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	100.0% 6/6 • Number of events 11 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	83.3% 5/6 • Number of events 7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	62.5% 5/8 • Number of events 6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	57.1% 4/7 • Number of events 8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	28.6% 2/7 • Number of events 4 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 5 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Immune system disorders Immune System Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Immune system disorders Infections and Infestations	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 5 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 5 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	62.5% 5/8 • Number of events 8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	57.1% 4/7 • Number of events 9 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	71.4% 5/7 • Number of events 10 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Injury, poisoning and procedural complications Injury, Poisoning and Procedural Complications	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	85.7% 6/7 • Number of events 8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Musculoskeletal and connective tissue disorders Muscoloskeletal and Connective Tissue Disorders	33.3% 2/6 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 4 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 5 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	25.0% 2/8 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	28.6% 2/7 • Number of events 8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	28.6% 2/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Nervous system disorders Nervous System Disorders	66.7% 4/6 • Number of events 8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	50.0% 3/6 • Number of events 9 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 4 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	62.5% 5/8 • Number of events 7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	85.7% 6/7 • Number of events 14 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	100.0% 7/7 • Number of events 13 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	66.7% 4/6 • Number of events 4 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Psychiatric disorders Psychiatric Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	28.6% 2/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Renal and urinary disorders Renal and Urinary Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Respiratory, thoracic and mediastinal disorders Respiratory, Thoracic and Mediastinal Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	28.6% 2/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Skin and subcutaneous tissue disorders Skin and Subcutaneous Tissue Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	33.3% 2/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Surgical and medical procedures Surgical and Medical Procedures	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Cardiac disorders Cardiac Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 2 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Investigations Investigations	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Metabolism and nutrition disorders Metabolism and Nutrition Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/7 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	14.3% 1/7 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.
Vascular disorders Vascular Disorders	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/6 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	0.00% 0/8 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	42.9% 3/7 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	42.9% 3/7 • Number of events 3 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.	16.7% 1/6 • Number of events 1 • Adverse event data was collected through the length of the participants enrollment in the study which was 44 weeks. Definition does not differ.

Additional Information

Executive Director, Clinical Development

Vaxxinity, Inc.

Phone: 254-244-5739

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place